Beyond Programmed Death-Ligand 1: B7-H6 Emerges as a Potential Immunotherapy Target in SCLC
Portia Thomas(Meharry Medical College), Christine M. Lovly(Dana-Farber Cancer Institute), Sarah M. Groves(University of Virginia), Jia Li(Zhejiang Chinese Medical University), Lisa M. Coussens(Oregon Health & Science University), Paula I. González-Ericsson(Breast Cancer Research Foundation), Prasad Kopparapu(Vanderbilt University Medical Center), Darren R. Tyson(Vanderbilt University), Cindy Lowe(Vanderbilt University Medical Center), Shamilene Sivagnanam(Oregon Health & Science University), Yingjun Yan(Vanderbilt University Medical Center), Courtney B. Betts(Oregon Health & Science University), Qi Liu(Vanderbilt University Medical Center), Heidi Chen(Vanderbilt University Medical Center), Yun-Kai Zhang(Vanderbilt University Medical Center), Vito Quaranta(Northeastern University), Kelli L. Boyd(Vanderbilt University Medical Center), Wade T. Iams(Vanderbilt University Medical Center)
Cited by 33
Related Papers
Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
|Cancer Cell|2012|4.7k
Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations
|Science|2002|2.7k
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k
Mechanisms of receptor tyrosine kinase activation in cancer
|Molecular Cancer|2018|1.1k
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021
|Journal of the National Comprehensive Cancer Network|2021|1k